Latest Insider Transactions at Oncternal Therapeutics, Inc. (ONCT)
This section provides a real-time view of insider transactions for Oncternal Therapeutics, Inc. (ONCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncternal Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncternal Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2022
|
Richard G Vincent Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,867
+29.71%
|
-
|
|
Jan 03
2022
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,867
+50.0%
|
-
|
|
Jan 03
2022
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
29,867
+48.78%
|
-
|
|
Jan 03
2022
|
James B Breitmeyer Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
6,793
+50.0%
|
-
|
|
Jan 03
2022
|
James B Breitmeyer Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
128,557
+25.07%
|
-
|
|
Jan 03
2022
|
Salim Yazji Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,137
+50.0%
|
-
|
|
Jan 03
2022
|
Rajesh Krishnan CTO/CSO |
BUY
Grant, award, or other acquisition
|
Direct |
29,867
+50.0%
|
-
|
|
Jun 30
2021
|
David F Hale |
SELL
Open market or private sale
|
Indirect |
3,669
-0.51%
|
$14,676
$4.75 P/Share
|
|
Jun 11
2021
|
Chase C. Leavitt General Counsel/Secretary |
BUY
Open market or private purchase
|
Direct |
1,500
+50.0%
|
$7,500
$5.45 P/Share
|